Ayala Pharmaceuticals Inc (ADXS)

[mastiffsforlife]

From today’s PR

“The Company plans to initiate a Phase 1/2 clinical trial that will seek to establish the safety, tolerability and effectiveness of ADXS-503 administered alone and in COMBINATION WITH A CHECKPOINT INHIBITOR in approximately 50 patients with metastatic NSCLC in different lines of therapy, at up to 20 centers across the U.S.”

Just wondering? Who’s checkpoint inhibitor do they have mind? I can only hope that this time we aren’t paying the bill for the combo part of the trial. I’m going to take a guess and say Merck will finally become a real partner with some upfront cash for these trials.